SLFN11 and metastatic malignant neoplasm: Median SLFN11 levels in colorectal cancers (CRC) (n = 144) (Supplementary Table 3) were modestly higher in patients with metastatic cancer compared to locally advanced disease (P = 0.030, Fig. 1f), and in patients with higher tumoural grade 3 compared to grade 2 (P = 0.022, Fig. 1g), but did not differ by CRC stage (Fig. 1h).